EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The atypical sphingolipid SPB 18:1(14Z);O2 is a biomarker for DEGS1 related hypomyelinating leukodystrophy

Andreas J Hülsmeier, Sandra P Toelle, Peter Bellstedt, Christian Wentzel, Angela Bahr, Konstantinos Kolokotronis, Thorsten Hornemann

Journal of Lipid Research · 2023-12 · 64 (12) · 100464

DOI: 10.1016/j.jlr.2023.100464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2023-12. Verfasst von Andreas J Hülsmeier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: andreas.huelsmeier@uzh.ch. Hauptthemen laut MEDLINE: Cogan Syndrome, Nervous System Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sphingolipids (SL) represent a structurally diverse class of lipids that are central to cellular physiology and neuronal development and function. Defects in the sphingolipid metabolism are typically associated with nervous system disorders. The C4-dihydroceramide desaturase (DEGS1) catalyzes the conversion of dihydroceramide to ceramide, the final step in the SL de-novo synthesis. Loss of function mutations in DEGS1 cause a hypomyelinating leukodystrophy, which is associated with increased plasma dihydrosphingolipids (dhSL) and with the formation of an atypical SPB 18:1(14Z);O2 metabolite. Here, we characterize two novel DEGS1 variants of unknown significance (VUS), provide a structural model with a predicted substrate binding site, and propose a regulatory link between DEGS1 and fatty acid desaturase 3 (FADS3). Both VUS involve single amino acid substitutions near the C-terminus within conserved regions of the enzyme. Patient 1 (p.R311K variant) shows severe progressive tetraspasticity, intellectual disability, and epilepsy in combination with brain magnetic resonance imaging (MRI) findings, typical for DEGS1-related leukodystrophy. Patient 2 (p.G270E variant) presents with delayed psychomotor development, oculomotor apraxia, and a normal brain MRI. Plasma from the p.R311K carrier showed a significantly elevated dhSL species and the presence of SPB 18:1(14Z);O2, while the plasma SL profile for the p.G270E variant was not altered. This suggests the p.R331K variant is pathogenic, while the p.G270E appears benign. As an increase in dihydroSL species is also seen in other pathological disorders of the SL metabolism, the SPB 18:1(14Z);O2 seems to be a more specific biomarker to discriminate between pathogenic and benign DEGS1 variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cogan SyndromeNervous System DiseasesHumansAmino Acid SubstitutionBiomarkersSphingolipidsFatty Acid Desaturases

Stichwörter der Autor:innen

DEGS1FADS3HLD18SPTSphingolipidsbiomarkerceramidehypomyelinating leukodystrophysphingolipidosis

Substanzen

BiomarkersSphingolipidsDEGS1 protein, humanFatty Acid Desaturases

Autor:innen und Institutionen

  • Institute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: andreas.huelsmeier@uzh.ch.
  • Department of Pediatric Neurology, University Children's Hospital, Zurich, University of Zurich, Zurich, Switzerland.
  • Institute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Women's and Children's Health, Pediatric Oncological and Neurological Research, Uppsala University, Uppsala, Sweden.
  • Institute of Medical Genetics, University of Zurich, Schlieren, Zurich, Switzerland.
  • Institute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: thorsten.hornemann@usz.ch.

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Hülsmeier, A. J., Toelle, S. P., Bellstedt, P., Wentzel, C., Bahr, A., Kolokotronis, K., & Hornemann, T. (2023). The atypical sphingolipid SPB 18:1(14Z);O2 is a biomarker for DEGS1 related hypomyelinating leukodystrophy. Journal of Lipid Research, 64(12), 100464. https://doi.org/10.1016/j.jlr.2023.100464

Vancouver

Hülsmeier AJ, Toelle SP, Bellstedt P, Wentzel C, Bahr A, Kolokotronis K, et al. The atypical sphingolipid SPB 18:1(14Z);O2 is a biomarker for DEGS1 related hypomyelinating leukodystrophy. Journal of Lipid Research. 2023;64(12):100464. doi:10.1016/j.jlr.2023.100464

BibTeX
@article{Hlsmeier2023,
  author = {Hülsmeier, Andreas J and Toelle, Sandra P and Bellstedt, Peter and Wentzel, Christian and Bahr, Angela and Kolokotronis, Konstantinos and Hornemann, Thorsten},
  title = {The atypical sphingolipid SPB 18:1(14Z);O2 is a biomarker for DEGS1 related hypomyelinating leukodystrophy},
  journal = {Journal of Lipid Research},
  year = {2023},
  volume = {64},
  number = {12},
  pages = {100464},
  doi = {10.1016/j.jlr.2023.100464}
}
Kostenlos starten →